 The number of patients receiving Percutaneous Coronary Intervention PCI is rapidly increasing in China. In 2013, about 450,000 Chinese patients received PCI, most of whom suffered from coronary heart disease CHD, especially acute coronary syndrome ACS. ACS is associated with an increased risk of cardiovascular mortality and recurrent cardiac events, underscoring the importance of identifying treatments that minimize this risk.The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering MIRACL trial suggested a benefit of lipid lowering with high-dose atorvastatin in patients with ACS. A meta-analysis of statin use in patients with ACS confirmed the benefits of early high-dose statin administration in decreasing recurrent myocardial ischemia, which suggested the clinical benefit and safety of statins were dose and statin dependent. The updated National Cholesterol Education Program Adult Treatment Panel III guidelines recommend that intensive therapy should be considered for all patients admitted to hospital for an ACS. Two meta-analyses have shown that early intensive statin therapy in patients with ACS is associated with a reduced rate of death and cardiovascular events. In the PROVE IT study, comparing atorvastatin 80 mg with pravastatin 40 mg, a significant reduction in major adverse clinical events was observed in favour of more intensive statin treatment. In that study, the median concentration of low-density LDL-C was lowered from 106 mgdL to 62 mgdL in the atorvastatin 80 mg group. More recently, the 2011 European Society of Cardiology ESC European Arterial Sclerosis Association EAS guideline for the management of dyslipidemia recommended patients with ACS are very high CV risk patients and should achieve LDL-C level 70 mgdl or 50 reduction. In 2011 American College of Cardiology Foundation ACCF American Heart Association AHA cardiovascular angiography and intervention Association Association of Cardiovascular angiography and intervention SCAI Guideline for PCI, statin therapy which lowers LDL to 70mgdL in very high-risk patients is recommended IIa, B. The latest China ACS consensus also recommends using the highest dose statin treatment for the acute phase and to attain an LDL-C level of 1.8 mmolL or 50 reduction compared with baseline in long-term treatment. However, there are very limited Chinese data demonstrating the current situation of lipid management LDL-C on-goal rate by different statins in real-world clinical practice. 